Leerink Partnrs Comments on Benitec Biopharma Inc.’s FY2024 Earnings (NASDAQ:BNTC)

Benitec Biopharma Inc. (NASDAQ:BNTC) – Equities research analysts at Leerink Partnrs issued their FY2024 EPS estimates for Benitec Biopharma in a research note issued on Monday, July 22nd. Leerink Partnrs analyst M. Foroohar anticipates that the biotechnology company will post earnings of ($5.45) per share for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($6.56) per share. Leerink Partnrs also issued estimates for Benitec Biopharma’s Q4 2024 earnings at ($0.53) EPS, FY2025 earnings at ($1.81) EPS and FY2026 earnings at ($1.83) EPS.

A number of other analysts also recently issued reports on the stock. SVB Leerink initiated coverage on shares of Benitec Biopharma in a report on Monday. They issued an “outperform” rating and a $13.00 price target on the stock. JMP Securities upped their price objective on Benitec Biopharma from $10.00 to $16.00 and gave the company a “market outperform” rating in a research report on Monday, April 22nd. Finally, Piper Sandler assumed coverage on Benitec Biopharma in a report on Thursday, June 13th. They issued an “overweight” rating and a $30.00 target price for the company.

Benitec Biopharma Stock Down 1.5 %

NASDAQ BNTC opened at $9.13 on Wednesday. The company has a current ratio of 4.18, a quick ratio of 4.18 and a debt-to-equity ratio of 0.01. Benitec Biopharma has a 12 month low of $1.86 and a 12 month high of $10.88. The stock’s 50 day moving average is $8.36 and its 200 day moving average is $6.16. The stock has a market cap of $85.55 million, a PE ratio of -4.91 and a beta of 0.91.

Benitec Biopharma (NASDAQ:BNTC) last issued its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($1.64) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Benitec Biopharma stock. Janus Henderson Group PLC boosted its holdings in shares of Benitec Biopharma Inc. (NASDAQ:BNTC) by 35.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 244,491 shares of the biotechnology company’s stock after acquiring an additional 64,092 shares during the quarter. Janus Henderson Group PLC owned 9.44% of Benitec Biopharma worth $1,266,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.